PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study
Daniel P. Petrylak, Nicholas J. Vogelzang, Kamal Chatta, Mark T. Fleming, David C. Smith, Leonard J. Appleman, Arif Hussain, Manuel Modiano, Parminder Singh, Scott T. Tagawa, Ira Gore, Edward F. McClay, Anthony E. Mega, A. Oliver Sartor, Bradley Somer, Raymond Wadlow, Neal D. Shore, William C. Olson, Nancy Stambler, Vincent A. DiPippoRobert J. Israel
Dive into the research topics of 'PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study'. Together they form a unique fingerprint.